Skip to main content

MiNK Therapeutics, Inc.

corporate_fare Company Profile

MiNK Therapeutics, Inc.

INKT·NASDAQ·Life Sciences·CIK 0001840229

MiNK Therapeutics, Inc. develops innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T ("iNKT") cells. iNKT cells are a distinct T cell population that combines the durable memory responses of adaptive T cells with the rapid, MHC-independent cytolytic capabilities of natural killer ("NK") cells. This dual functionality allows for direct tumor killing, orchestration of the tumor microenvironment, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function, while naturally suppressing graft-versus-host disease ("GvHD"). This makes iNKT cells an optimal platform for allogeneic therapy due to their natural homing capabilities, tumor clearance potential, and efficacy against infected cells. The company advances both native and engineered iNKT cell therapies through a pipeline of wholly owned or exclusively licensed assets. MiNK Therapeutics has also developed a proprietary personalized neoantigen library to facilitate personalized T Cell Receptor ("TCR") development. This library identifies patient-specific tumor neoantigens to create tailored TCR-based therapies, aiming to enhance precision, efficacy, and therapeutic outcomes for patients with various cancers and immune-mediated diseases. The company's goal is to discover, develop, and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies for cancer and other immune-mediated diseases with high unmet needs. MiNK Therapeutics employs iNKT cells in their native form through its lead program, agenT-797, in diseases where iNKT cells have shown activity and accelerated approval pathways exist. These indications include critical pulmonary immune failure (including severe hypoxemic respiratory failure / pneumonia), GvHD, solid tumor cancers, and other severe immune-related diseases.

MiNK Therapeutics, Inc. (NASDAQ:INKT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for INKT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for INKT spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • MiNK 10-Q: Going-Concern Warning, $7.5M Cash, First $0.2M Product Revenue
  • MiNK Matches Loss Estimates but Revenue Comes In at $200K vs $875K Expected
  • MiNK's agenT-797 Selected for $87M ARPA-H Room-Temperature Cell Therapy Program
  • MiNK Reports Narrower Q2 Loss and First Randomized Phase 2 Data for agenT-797
  • MiNK's agenT-797 Shows Early Survival Signal in Randomized ARDS Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$12.49M
Diluted EPS
-$2.93
Op. Cash Flow
-$5.93M
Operating Income
-$12.64M
Cash & Equivalents
$13.36M
Debt / Equity
0.00×
Shares Outstanding
4.27M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-134813

Short Interest & Short Volume

4.29 days to cover

FINRA reported short interest of 55,094 shares in INKT as of the October 30, 2026 settlement, a 15.3% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 32.3% of INKT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)55,094 shares as of October 30, 2026
Change vs prior period▲ 15.3%
Days to cover4.29 at avg daily volume of 12,851
Daily short volume (FINRA facilities)32.3% of 11,271 shares on November 20, 2026
5-day average short volume37.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$8.58 -0.33% today
52-week range · as of 2026-11-12 $8.48 – $16.93
Market cap
$41.17M
Volume
19K (1.4× avg)
3-mo avg 14K
Live data · 2026-11-22 04:04 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INKT - Latest Insights

INKT
Nov 12, 2026, 10:05 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.08
Real-time Price: $8.58 info
Change: -$1.50 (-15%) info
Market Cap: $41.172M info
INKT
Nov 11, 2026, 9:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $10.00
Real-time Price: $8.58 info
Change: -$1.42 (-14%) info
Market Cap: $41.172M info
INKT
Sep 30, 2026, 7:57 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $15.93
Real-time Price: $8.58 info
Change: -$7.35 (-46%) info
Market Cap: $41.172M info
INKT
Aug 13, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.08
Real-time Price: $8.58 info
Change: -$2.50 (-23%) info
Market Cap: $41.172M info
INKT
Aug 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.08
Real-time Price: $8.58 info
Change: -$2.50 (-23%) info
Market Cap: $41.172M info
INKT
May 15, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.95
Real-time Price: $8.58 info
Change: -$2.37 (-22%) info
Market Cap: $41.172M info
INKT
May 15, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.59
Real-time Price: $8.58 info
Change: -$3.00 (-26%) info
Market Cap: $41.172M info
INKT
May 15, 2026, 7:39 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $10.92
Real-time Price: $8.58 info
Change: -$2.34 (-21%) info
Market Cap: $41.172M info
INKT
May 12, 2026, 7:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.95
Real-time Price: $8.58 info
Change: -$2.37 (-22%) info
Market Cap: $41.172M info
INKT
Apr 30, 2026, 4:38 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $12.20
Real-time Price: $8.58 info
Change: -$3.62 (-30%) info
Market Cap: $41.172M info
INKT
Apr 17, 2026, 3:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.40
Real-time Price: $8.58 info
Change: -$5.82 (-40%) info
Market Cap: $41.172M info
INKT
Mar 31, 2026, 4:49 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $10.53
Real-time Price: $8.58 info
Change: -$1.95 (-19%) info
Market Cap: $41.172M info
INKT
Mar 31, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.81
Real-time Price: $8.58 info
Change: -$2.23 (-21%) info
Market Cap: $41.172M info
INKT
Mar 27, 2026, 10:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.70
Real-time Price: $8.58 info
Change: -$2.12 (-20%) info
Market Cap: $41.172M info
INKT
Mar 10, 2026, 5:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.12
Real-time Price: $8.58 info
Change: -$1.54 (-15%) info
Market Cap: $41.172M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets